CSL (ASX:CSL) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CSL Panoramica delle azioni

CSL Limited ricerca, sviluppa, produce, commercializza e distribuisce biofarmaci e vaccini in Australia, Stati Uniti, Germania, Regno Unito, Svizzera, Cina, Hong Kong e a livello internazionale.

Informazioni sull'azienda

CSL analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	2/6
Prestazioni passate	5/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 12.85% all'anno

Gli utili sono cresciuti del 20.4% nell'ultimo anno

Analisi del rischio

Ha un alto livello di debito

CSL Limited Concorrenti

Clinuvel Pharmaceuticals

ASX:CUV

AU$703.6m

Gilead Sciences

NasdaqGS:GILD

US$91.9b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$127.3b

Amgen

NasdaqGS:AMGN

US$172.7b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per CSL
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$308.25
Massimo di 52 settimane	AU$313.55
Minimo di 52 settimane	AU$228.65
Beta	0.31
1Variazione di 1 mese	-1.11%
Variazione a 3 mesi	10.85%
Variazione di 1 anno	16.70%
3Variazione a 3 anni	-0.097%
Variazione a 5 anni	31.70%
Variazione dall'IPO	38,431.64%

Notizie e aggiornamenti recenti

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

Recent updates

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Jan 19

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

Dec 08

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Oct 26

Rendimenti per gli azionisti

	CSL	AU Biotechs	AU Mercato
7D	4.6%	-0.004%	2.2%
1Y	16.7%	17.2%	11.2%

Ritorno vs Industria: CSL ha trovato corrispondenza nel Australian Biotechs che ha restituito 17.2 % nell'ultimo anno.

Rendimento vs Mercato: CSL ha superato il mercato Australian che ha restituito 10.6 % nell'ultimo anno.

Volatilità dei prezzi

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.4%
Biotechs Industry Average Movement	11.8%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: CSL non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 2% ) di CSL è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited ricerca, sviluppa, produce, commercializza e distribuisce biofarmaci e vaccini in Australia, Stati Uniti, Germania, Regno Unito, Svizzera, Cina, Hong Kong e a livello internazionale. L'azienda opera attraverso i segmenti CSL Behring, CSL Seqirus e CSL Vifor. Il segmento CSL Behring offre prodotti a base di plasma, terapie geniche e ricombinanti.

CSL Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di CSL con la sua capitalizzazione di mercato?
CSL statistiche fondamentali
Capitalizzazione di mercato	AU$148.75b
Guadagni(TTM)	AU$3.93b
Ricavi(TTM)	AU$22.03b

37.9x

Rapporto P/E

6.8x

Rapporto P/S

CSL è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CSL Conto economico (TTM)
Ricavi	US$14.80b
Costo del fatturato	US$7.10b
Profitto lordo	US$7.71b
Altre spese	US$5.06b
Guadagni	US$2.64b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Feb 11, 2025

Utile per azione (EPS)	5.47
Margine lordo	52.06%
Margine di profitto netto	17.85%
Rapporto debito/patrimonio netto	54.2%

Come si è comportato CSL nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.3%

Rendimento attuale del dividendo

48%

Rapporto di remunerazione

CSL paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di CSL

Quando è necessario acquistare CSL per ricevere un dividendo imminente?
CSL date dei dividendi
Data di stacco del dividendo	Sep 09 2024
Data di pagamento dei dividendi	Oct 02 2024
Giorni fino al dividendo Ex	19 days
Giorni prima della data di pagamento dei dividendi	42 days

CSL paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di CSL

CSL Panoramica delle azioni

Premi

Analisi del rischio

CSL Limited Concorrenti

ASX:CUV

AU$703.6m

NasdaqGS:GILD

US$91.9b

NasdaqGS:REGN

US$127.3b

NasdaqGS:AMGN

US$172.7b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Recent updates

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates